monoclonal antibodies

AMA Update 140: Vaccine trials ramp up for possible fourth dose in fall with Andrea Garcia, JD, MPH

AMA CXO Todd Unger reviews COVID-19 vaccine numbers and trending topics related to the pandemic over the past week with AMA Director of Science, Medicine and Public Health Andrea Garcia. Also covering updates from FDA’s vaccine advisory committee meeting regarding a revised version of the COVID vaccine for fall, the FDA suspending use of a monoclonal antibody drug by GlaxoSmithKline known as sotrovimab to treat high-risk COVID-19 patients in the U.S. because it’s unlikely to be effective against BA.2, and a clinical trial published in NEJM confirms that the anti-parasitic drug, ivermectin, showed no sign of alleviating COVID.

Read More

AMA Update 121: Gerald Harmon, MD, on what physicians need to know about COVID-19 therapeutics

AMA CXO Todd Unger is joined by the AMA’s president, Gerald Harmon, MD, a family medicine specialist in Pawleys Island, S.C., who shares new information and big takeaways about therapeutics for COVID-19 after his recent conversation with three physician leaders from the FDA.

Read More

AMA Update 55: Dr. Michael Anderson discusses what physicians need to know about monoclonal antibodies

A discussion with with Dr. Michael Anderson, senior advisor at the HHS Office of the Assistant Secretary for Preparedness and Response in Washington, D.C., about what physicians need to know about monoclonal antibody treatments and their incredible effectiveness in helping certain patients avoid hospitalization for COVID-19. 

Read More